Idera Pharmaceuticals, Inc.
(NASDAQ : IDRA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
0.67%345.221.2%$624.02m
GILDGilead Sciences, Inc.
-3.53%72.920.9%$510.71m
CELGCelgene Corporation
0.24%90.371.2%$496.41m
AMGNAmgen Inc.
0.50%197.421.2%$485.34m
ILMNIllumina, Inc.
-0.34%325.883.5%$373.70m
REGNRegeneron Pharmaceuticals, Inc.
0.67%374.262.6%$315.78m
VRTXVertex Pharmaceuticals Incorporated
0.64%176.081.9%$209.08m
ALXNAlexion Pharmaceuticals, Inc.
-1.09%116.002.0%$186.59m
AAgilent Technologies, Inc.
-1.28%64.661.5%$159.27m
SRPTSarepta Therapeutics, Inc.
0.52%130.2516.6%$142.46m
NKTRNektar Therapeutics
0.13%60.035.6%$126.29m
BLUEBluebird Bio, Inc.
1.15%158.0014.6%$121.57m
EXASExact Sciences Corporation
0.33%48.8425.3%$118.82m
BMRNBioMarin Pharmaceutical Inc.
0.69%101.014.4%$118.74m
INCYIncyte Corporation
1.40%68.802.5%$111.73m

Company Profile

Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which focuses on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. The firm uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.